Biopharmaceutical company Orphazyme A/S (CPH: ORPHA.CO), which is dedicated to developing treatments for patients living with rare diseases, announced on Tuesday that it has entered into a structured debt facility (loan agreement) with Kreos Capital VI (UK) Limited (Kreos) to secure funding of EUR9m.
Various customary fees will be paid by the company to Kreos for the establishment of the loan upon execution of the loan agreement, as well as in connection with drawn down and a facilitation fee payable at Kreos' discretion prior to the earlier of eight years or delisting, the company added.
Pursuant to this termination agreement, SuperSonic Imagine will be definitively and fully discharged of any obligation towards Kreos
Capital V Ltd.
Kreos has announced the launch of Kreos Capital VI, its latest, and to date largest growth debt fund, with EUR 700 million (USD 800 million), reinforcing its commitment to the European and Israeli growth ecosystem, the company said.
Kreos VI has been oversubscribed, reflecting Kreos's successful 20-year track-record and strong market position, experienced and stable organization, and continuous evolution of its growth debt model to support high-growth companies and their equity investors with tailored and non-dilutive financing solutions.
continues to support the growth ecosystem in Europe and Israel with its debt financing solutions.
M2 EQUITYBITES-February 14, 2019-Kreos Capital launches EUR 700m Kreos
Capital VI fund
As of 30 September 2018, the company had a net cash position of USD4.9m and a EUR20m financing agreement was signed with Kreos
Capital in July 2018.
M2 EQUITYBITES-February 2, 2018-Bonesupport Holding's subsidiary repays outstanding loan from Kreos
* On January 25, 2019, we announced that we had entered into a bond financing for up to [euro]20 million from Kreos
The company revealed that it will use USD22.4m of the loan proceeds to repay the remaining obligations under its loan agreements with Oxford Finance LLC, Silicon Valley Bank and Kreos
Capital III (UK) Limited; to fund the ongoing commercial launch of DUEXIS in the US and pursue regulatory approval for DUEXIS in Europe and LODOTRA in the US.